Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;172(6):747-751.
doi: 10.1007/s10517-022-05470-x. Epub 2022 May 2.

Early Diagnostic Markers and Therapeutic Targets for Experimental Breast Cancer

N N Ermakova  1 , O V Pershina  1 , M A Zhukova  1 , A V Pakhomova  1 , E S Pan  1 , L A Sandrikina  1 , V A Krupin  1 , O Yu Rybalkina  1 , A M Dygai  1   2 , E G Skurikhin  3
Affiliations

Early Diagnostic Markers and Therapeutic Targets for Experimental Breast Cancer

N N Ermakova et al. Bull Exp Biol Med. 2022 Apr.

Abstract

Various stem cells were studied in female BALB/c mice at the early terms after administration of N-methyl-N-nitrosourea to search early diagnostic markers and therapeutic targets. At these terms, damage to the epithelium and endothelium, inflammation, and fibrosis were observed in the mammary gland, but the tumor was not detected. Cancer stem cells, hematopoietic stem cells (HSC), hematopoietic progenitor cells, angiogenic precursors, and epithelial progenitor cells were found in the blood and mammary gland. Cancer stem cells (CD44+CD24-) are proposed as the early diagnostic marker of breast cancer, and short-living HSC, hematopoietic progenitor cells, and angiogenic precursors (CD45-CD117+FLK-1+) as predictors of the formation of tumor microenvironment.

Keywords: breast cancer; diagnostic markers; early diagnosis and treatment; stem cells; therapeutic targets.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Agnoletto C, Corrà F, Minotti L, Baldassari F, Crudele F, Cook WJJ, Di Leva G, d’Adamo AP, Gasparini P, Volinia S. Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. Cancers (Basel). 2019;11(4):483. doi: https://doi.org/10.3390/cancers11040483 - DOI - PMC
    1. Aravindhan S, Ejam SS, Lafta MH, Markov A, Yumashev AV, Ahmadi M. Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature. Cancer Cell Int. 2021;21(1):158. doi: https://doi.org/10.1186/s12935-021-01836-9 - DOI - PubMed - PMC
    1. Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA. Molecular markers for breast cancer: prediction on tumor behavior. Dis. Markers. 2014;2014:513158. doi: https://doi.org/10.1155/2014/513158 - DOI - PubMed - PMC
    1. Coughlin SS. Epidemiology of Breast Cancer in Women. Adv. Exp. Med. Biol. 2019;1152:9-29. doi: https://doi.org/10.1007/978-3-030-20301-6_2 - DOI - PubMed
    1. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur. J. Cancer. 2017;75:284-298. doi: https://doi.org/10.1016/j.ejca.2017.01.017 - DOI - PubMed

LinkOut - more resources